SOUTH
SAN FRANCISCO, Calif., Feb. 1, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced its participation
in upcoming investor relations events.
Oppenheimer 34th Annual Healthcare Life Sciences
Conference
Wednesday, February 14th,
2024 at 1:20 PM ET
- Fireside chat with Yujiro S. Hata, Chief Executive
Officer, hosted by Matthew Biegler,
Executive Director and Senior Analyst
Citi's 2024 Virtual Oncology Leadership Summit
Wednesday, February 21st,
2024 at 11:00 AM ET
- Fireside chat with Darrin Beaupre, Chief Medical Officer
and Michael White, Chief Scientific
Officer, hosted by Yigal D.
Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
A live audio webcast of conference events, as permitted by
conference host, will be available at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events and/or through the conference
host. A replay of available webcasts will be accessible for
30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Quarterly Report on Form 10-Q filed on November 7, 2023 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2024-investor-relations-events-302049960.html
SOURCE IDEAYA Biosciences, Inc.